HC Wainwright Issues Optimistic Outlook for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Equities researchers at HC Wainwright increased their Q2 2026 EPS estimates for Greenwich LifeSciences in a research note issued on Tuesday, July 21st. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.30) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $69.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ FY2026 earnings at ($1.29) EPS and FY2027 earnings at ($1.17) EPS.

GLSI has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen lowered shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $57.00.

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences stock opened at $13.27 on Thursday. The stock has a market cap of $194.80 million, a PE ratio of -8.45 and a beta of 1.40. The firm’s 50-day simple moving average is $22.69 and its 200 day simple moving average is $24.50. Greenwich LifeSciences has a fifty-two week low of $7.78 and a fifty-two week high of $34.10.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors have recently made changes to their positions in GLSI. Bank of America Corp DE raised its position in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after acquiring an additional 4,102 shares during the last quarter. Rhumbline Advisers raised its position in Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Greenwich LifeSciences during the fourth quarter valued at approximately $203,000. Finally, Barclays PLC increased its position in Greenwich LifeSciences by 11.8% during the 4th quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after purchasing an additional 1,030 shares during the period. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences News Summary

Here are the key news stories impacting Greenwich LifeSciences this week:

• Positive Sentiment: HC Wainwright boosted its price target on Greenwich LifeSciences to $69 from $50 and kept a Buy rating, signaling confidence in the company’s long-term potential. HC Wainwright raises GLSI price target
• Positive Sentiment: The company received UK regulatory approval to expand its Phase III FLAMINGO-01 breast cancer trial, adding a possible 5-10 new sites and widening the patient pool for GLSI-100. GlobeNewswire UK trial expansion release
• Positive Sentiment: Management highlighted preliminary FLAMINGO-01 data showing an approximately 70-80% reduction in recurrence rates after the primary immunization series, which supports the drug’s clinical promise, though the data remain early. Quiver summary of FLAMINGO-01 data

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.